Recursion Pharmaceuticals (RXRX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- AI Drug Discoverysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 48/100 (MEDIUM), 16.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Recursion Pharmaceuticals (RXRX) Reached A $10 Million Immunology Milestone
- Iambic CEO on taking an AI drug company public
- Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar
- RXRX Stock Heads For Its Best Day In Over A Year – What’s Driving The Rally Today?
- Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
- Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
- Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
- What Could Go Wrong With Recursion Pharmaceuticals Stock?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Recursion Pharmaceuticals.
Full RXRX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.